# Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU

> **NCT02205541** · PHASE3 · COMPLETED · sponsor: **University Hospital, Toulouse** · enrollment: 100 (actual)

## Conditions studied

- Hemolytic Uremic Syndrome of Childhood

## Interventions

- **DRUG:** Eculizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02205541
- **Lead sponsor:** University Hospital, Toulouse
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2018-06
- **Final completion:** 2018-06
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02205541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02205541, "Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02205541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*